Replies to post #37414 on Relief Therapeutics Holding AG (RLFTF)

[tcm55]

NRX/RLF are targeting the sickest patients with the EAP using ""ZYESAMI"" . I notice that all Refs for RLF-100 are now changed to ZYESAMI as of 3-19.

As said before, there are more Patients treated in the EAP CT than the Main 'less critical' Patient's IV CT.

Gathering ALL Available Data for Aviptadil / RLF-100 / ZYESAMI for inclusion in a FDA presentation and Application(s) makes basic sense. The CTs NEW DATA Supports the Application(s) for an EUA, IMO. If they can pull together (Interim) Data from the UC / St. Jude Inhaler study, GREAT.
Target Groups, of course. Both Short and Long term Data Results, Duh.


https://clinicaltrials.gov/ct2/history/NCT04453839?A=5&B=6&C=Side-by-Side#StudyPageTop


...NRLA...

GEM and Insider's stock prices are the same as Ours. They have the BALL and want this all to succeed as much as we do...GLTA...